Search clinical trials for: CC-115

Total 2945 results

Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
Johnson & Johnson Vision Care, Inc.

Completed

Evaluating Soft Contact Lens Prototypes for Myopia Control

Visual Acuity

China
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Celgene

Completed

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Neoplasm Metastasis | Prostate Cancer | Chronic Lymphocytic Leukemia | Glioblastoma Multiforme | Squamous Cell Carcinoma of Head and Neck | Ewing's Osteosarcoma

United States, Spain, France, Germany
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Celgene

Completed

Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants

Healthy Volunteers

Belgium
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
National Institute of Mental Health (NIMH)

Completed

Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112

Healthy

United States
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Columbia University

Terminated

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Breast Cancer | Colon Cancer | Neuropathy

United States
Chung Shan Medical University

Completed

HFCWO on Pneumonic Respiratory Failure (HFCWOonAFR)

Pneumonia | Acute Respiratory Failure
Gilead Sciences

Terminated

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States
Hope Medicine (Nanjing) Co., Ltd

Recruiting

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Androgenetic Alopecia

China
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
Penn State University
Jenny Craig, Inc.

Completed

The Influence of Satiation Measures on the Portion Size Effect

Feeding Behavior

United States
Ascentage Pharma Group Inc.

Completed

APG-115 in Patients With Advanced Solid Tumors or Lymphomas (APG-115)

Patients With Advanced Solid Tumor or Lymphoma

United States
Biocad

Completed

Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Breast Cancer

Russian Federation
TargeGen

Completed

Safety of TG100-115 for Heart Attack Treated With Angioplasty

Myocardial Infarction

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Hope Medicine (Nanjing) Co., Ltd

Completed

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Androgenetic Alopecia

Australia
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Tego Science, Inc.

Completed

Phase 1/2 Clinical Study of TPX-115 in Patients With Partial-Thickness Rotator Cuff Tear

Rotator Cuff Injuries

Korea, Republic of
Aptabio Therapeutics, Inc.

Completed

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Diabetes Mellitus, Type 2 | Diabetic Nephropathies | Nephropathy, Diabetic

Bulgaria, Czechia, Hungary, Serbia
Dow Pharmaceutical Sciences

Completed

A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

Rosacea

United States
Aptabio Therapeutics, Inc.

Completed

Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers

Healthy | Safety

France
Aptabio Therapeutics, Inc.
Covance

Terminated

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

COVID-19

United States
Radboud University Medical Center
Norgine

Unknown

Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial (EXCEED)

Colorectal Neoplasms

Netherlands, Greece
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Solid Tumor | Neuroblastoma

China
University of North Carolina, Chapel Hill
Boston Children's Hospital; Medical College of Wisconsin; National Football League

Enrolling by invitation

NFL LONG Prospective Study

Concussion, Brain

United States
Gilead Sciences

Completed

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Chronic Lymphocytic Lymphoma

United States
Ascentage Pharma Group Inc.

Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

T-Prolymphocytic Leukemia

United States
Protalix

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Gout

New Zealand
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Dana-Farber Cancer Institute

Completed

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

Multiple Myeloma

United States
Aptabio Therapeutics, Inc.

Recruiting

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Contrast Induced Acute Kidney Injury

Korea, Republic of, United States
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia

3

Subscribe